Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

From US Department of Health & Human Services: National Institutes of Health (NIH)

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

Type of Support

Overview

This grant program outlines specific deadlines for the submission of Letters of Intent and full proposal applications, indicating a structured, periodic review process for grant consideration. While it does not specify the broad goals or guiding principles directly, the systematic approach suggests a well-organized and possibly competitive grant program focused on supporting projects or causes that align with predetermined cycles and possibly thematic areas of interest. The inclusion of multiple deadlines over a span of years hints at an ongoing opportunity for funding, supporting a range of initiatives over time. Specific causes supported are not mentioned, emphasizing the need for applicants to contact program officers for detailed information, including the funder's mission, thematic areas of interest, and eligibility criteria.

Eligibility

Organization's Location
proident voluptate
Program Location
elit
Organization Type
not specified

Submission

Visit Apply for more information.